7 articles
NVIDIA's BioNeMo platform has secured partnerships with Thermo Fisher and Eli Lilly, embedding AI into core drug discovery pipelines across North America and Europe. Denmark's Novo Nordisk surged 24.9% in 30 days after licensing its cell therapy program to an AI-native partner. FDA Fast Track designation for an AI-assisted Parkinson's therapy signals that regulators are beginning to validate the model.
NVIDIA's BioNeMo has secured partnerships with Eli Lilly and Thermo Fisher, establishing itself as shared infrastructure for AI-driven drug discovery worldwide. Five AI biotech platforms launched in rapid succession, signaling faster-than-expected commoditization of biotech AI tooling. Novo Nordisk's Parkinson's licensing deal with Cellular Intelligence illustrates how large pharma globally is offloading early-stage biology to AI-native specialists.
Danish pharma giant Novo Nordisk posted a 24.9% single-session stock gain after shuttering its cell therapy unit and handing its Parkinson's program to an AI-native firm. The move signals a structural break across global pharmaceuticals: investors are rewarding asset-light, AI-accelerated models over traditional in-house research. NVIDIA's BioNeMo platform is emerging as the shared infrastructure binding legacy multinationals to a new generation of AI drug-discovery specialists.
Paradigm Health has gone live with its Study Conduct platform for Phase 1b and Phase 2 trials with both Amgen and AstraZeneca at the same time—before the system has any operational track record. The dual launch concentrates risk: EHR failures, algorithmic misclassification, and data ingestion errors could each invalidate trial results. With the FDA's real-time oversight model on the line, how Paradigm manages this window will shape AI's credibility in global drug development.
Biolojic Design's BD200 demonstrated superior tumor uptake compared to marketed antibody-drug conjugates in dual-expressing breast cancer cells, becoming the first AI-designed antibody to reach clinical trials. The dual-targeting approach showed efficacy in patient-derived models resistant to existing ADCs, compressing development timelines that typically span years across global pharmaceutical pipelines.
As AI-powered clinical decision support tools spread across healthcare systems worldwide, the risk of 'hallucinations' — confidently delivered but factually wrong medical guidance — is emerging as a critical patient safety challenge. The case of Epocrates, a tool used by millions of clinicians globally, illustrates how the race to embed generative AI into medical workflows is outpacing regulatory frameworks on every continent.
French-American biotech Cellectis is preparing a landmark FDA filing for its allogeneic CAR-T therapy lasme-cel, targeting a $700M peak sales opportunity across the US and Europe by 2035 — with a potential $1.3B upside if label expansions succeed. The move positions Cellectis at the frontier of a global shift away from costly, patient-specific cell therapies toward scalable, off-the-shelf alternatives. A deepening partnership with AstraZeneca and dual manufacturing facilities on two continents u